Skip to content


Symdeko, Kaftrio (tezacaftor) is a small molecule pharmaceutical. Tezacaftor was first approved as Symdeko on 2018-02-12. It has been approved in Europe to treat cystic fibrosis. It is known to target cystic fibrosis transmembrane conductance regulator. Symdeko's patents are valid until 2035-04-14 (FDA).
Trade Name Kaftrio
Common Name Tezacaftor
Indication cystic fibrosis
Drug Class Cystic fibrosis transmembrane regulator (CFTR) protein modulators
Get full access now